Ipsen
Clinical trials sponsored by Ipsen, explained in plain language.
-
New hope for AML patients: experimental drug IPN60340 enters key trial
Disease control Not yet recruitingThis study tests whether adding the experimental drug IPN60340 to standard medicines (azacitidine and venetoclax) helps more people with newly diagnosed acute myeloid leukemia (AML) achieve complete remission. About 450 adults who cannot have intensive chemotherapy will take part…
Phase: PHASE2, PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New study tracks Real-World safety of odevixibat in rare liver disease
Disease control Not yet recruitingThis study will follow 30 people with Alagille syndrome who are taking odevixibat in their daily lives. The goal is to see how safe the drug is over the long term by tracking any side effects. It is not testing if the drug works, but rather monitoring its real-world safety.
Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New study tracks pregnancy risks for elafibranor users
Knowledge-focused Not yet recruitingThis study follows people who took elafibranor shortly before or during pregnancy to see if it affects the baby or mother. Researchers will collect information from medical records and safety reports over about 10 years. No extra tests or treatments are required—only routine care…
Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC